FDA Will Encourage Voluntary Reporting of LDT Adverse Events to MedWatch System

Although FDA is still practicing regulatory enforcement discretion for the majority of laboratory-developed tests, the agency will put in place mechanisms allowing voluntary reporting of adverse events and malfunctions associated with LDTs through its MedWatch system.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.